Skip to main content

Advertisement

Table 5 Secondary endpoints - pain over the last 24 hours and global patient assessment on disease activity evaluated at each visit on a VAS (100 mm)

From: Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial

  N Pain (VAS) P value Disease activity P value
V1 22 49.41 ± 24.94 ns 60.00 ± 22.67 ns
V2 22 50.95 ± 23.85 ns 58.32 ± 20.37 ns
V3 21 44.52 ± 27.41 ns 48.71 ± 27.37 ns
V4 20 42.20 ± 26.33 ns 42.70 ± 25.82 ns
V5 20 39.20 ± 28.96 ns 38.85 ± 27.66 0.0047*
  1. *p value versus V1. Data are mean ± sd and were analyzed with Student t-test. V1: first visit, at the time of selection; V2: visit after 7 days of treatment; V3: visit after 14 days of treatment; V4: visit after 28 days of treatment; V5: visit after 84 days of treatment.